Literature DB >> 21440654

Trends of hematopoietic stem cell transplantation in the Eastern Mediterranean region, 1984-2007.

Syed O A Ahmed1, Ardeshir Ghavamzadeh, Syed Z Zaidi, Helen Baldomero, Marcelo C Pasquini, Fazal Hussain, Kamran Alimoghaddam, Fahad Almohareb, Mouhab Ayas, Amir Hamidieh, Hossam K Mahmoud, Alaa Elhaddad, Tarek Ben Othman, Abdelrahman Abdelkefi, Mahmoud Sarhan, Fawzi Abdel-Rahman, Salman Adil, Salam Alkindi, Ali Bazarbachi, Said Benchekroun, Dietger Niederwieser, Mary Horowitz, Alois Gratwohl, Hassan El Solh, Mahmoud Aljurf.   

Abstract

Hematopoietic stem cell transplantation (HSCT) activity was surveyed in the 9 countries in the World Health Organization Eastern Mediterranean region that reported transplantation activity. Between the years of 1984 and 2007, 7933 transplantations were performed. The number of HSCTs per year has continued to increase, with a plateau in allogeneic HSCT (allo-HSCT) between 2005 and 2007. Overall, a greater proportion of transplantations were allo-HSCT (n = 5761, 77%) compared with autologous HSCT (ASCT) (n = 2172, 23%). Of 5761 allo-HSCT, acute leukemia constituted the main indication (n = 2124, 37%). There was a significant proportion of allo-HSCT for bone marrow failures (n = 1001, 17%) and hemoglobinopathies (n = 885, 15%). The rate of unrelated donor transplantations remained low, with only 2 matched unrelated donor allo-HSCTs reported. One hundred umbilical cord blood transplantations were reported (0.017% of allo-HSCT). Peripheral blood stem cells were the main source of graft in allo-HSCT, and peripheral blood stem cells increasingly constitute the main source of hematopoietic stem cells overall. Reduced-intensity conditioning was utilized in 5.7% of allografts over the surveyed period. ASCT numbers continue to increase. There has been a shift in the indication for ASCT from acute leukemia to lymphoproliferative disorders (45%), followed by myeloma (26%). The survey reflects transplantation activity according to the unique health settings of this region. Notable differences in transplantation practices as reported to the European Group for Blood and Marrow Transplantation over recent years are highlighted.
Copyright © 2011 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21440654      PMCID: PMC3371191          DOI: 10.1016/j.bbmt.2011.01.019

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  31 in total

1.  Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe.

Authors:  A Urbano-Ispizua; N Schmitz; T de Witte; F Frassoni; G Rosti; H Schrezenmeier; E Gluckman; W Friedrich; C Cordonnier; G Socie; A Tyndall; D Niethammer; P Ljungman; A Gratwohl; J Apperley; D Niederwieser; A Bacigalupo
Journal:  Bone Marrow Transplant       Date:  2002-04       Impact factor: 5.483

2.  Evolution of hematopoietic stem cell transplantation in Eastern and Western Europe from 1990 to 2003. A report from the EBMT activity survey.

Authors:  Alois Gratwohl; Helen Baldomero; Boris Labar; Jane Apperley; Alvaro Urbano-Ispizua
Journal:  Croat Med J       Date:  2004-12       Impact factor: 1.351

3.  Haematopoietic stem cell transplantation (HSCT) in Europe 2002. Changes in indication and impact of team density. A report of the EBMT activity survey.

Authors:  A Gratwohl; O Schmid; H Baldomero; B Horisberger; A Urbano-Ispizua
Journal:  Bone Marrow Transplant       Date:  2004-11       Impact factor: 5.483

4.  Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe: a report of the EBMT activity survey 2003.

Authors:  A Gratwohl; H Baldomero; O Schmid; B Horisberger; M Bargetzi; A Urbano-Ispizua
Journal:  Bone Marrow Transplant       Date:  2005-10       Impact factor: 5.483

Review 5.  Hematopoietic stem-cell transplantation.

Authors:  Edward A Copelan
Journal:  N Engl J Med       Date:  2006-04-27       Impact factor: 91.245

6.  Prognostic factors in bone marrow transplantation for beta thalassemia major: experiences from Iran.

Authors:  A Ghavamzadeh; P Nasseri; M R Eshraghian; M Jahani; I Baybordi; J Nateghi; A Khodabandeh; A R Sadjadi; M Mohyeddin; Y Khademi
Journal:  Bone Marrow Transplant       Date:  1998-12       Impact factor: 5.483

7.  Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial.

Authors:  Norbert Schmitz; Meral Beksac; Andrea Bacigalupo; Tapani Ruutu; Arnon Nagler; Eliane Gluckman; Nigel Russell; Jane Apperley; Jeff Szerm; Kenneth Bradstock; Agnes Buzyn; Brigitte Schlegelberger; James Matcham; Alois Gratwohl
Journal:  Haematologica       Date:  2005-05       Impact factor: 9.941

8.  Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT).

Authors:  R E Champlin; N Schmitz; M M Horowitz; B Chapuis; R Chopra; J J Cornelissen; R P Gale; J M Goldman; F R Loberiza; B Hertenstein; J P Klein; E Montserrat; M J Zhang; O Ringdén; S C Tomany; P A Rowlings; M E Van Hoef; A Gratwohl
Journal:  Blood       Date:  2000-06-15       Impact factor: 22.113

9.  Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation.

Authors:  N Schmitz; A Bacigalupo; D Hasenclever; A Nagler; E Gluckman; P Clark; P Bourquelot; H Greinix; N Frickhofen; O Ringdén; A Zander; J F Apperley; C Gorin; K Borkett; G Schwab; M Goebel; N H Russell; A Gratwohl
Journal:  Bone Marrow Transplant       Date:  1998-05       Impact factor: 5.483

10.  Present and future of hematology and stem cell transplantation in Morocco.

Authors:  S Benchekroun; M Harif; A Madani; A Quessar; S Zafad; R Rachid
Journal:  Bone Marrow Transplant       Date:  2008-08       Impact factor: 5.483

View more
  6 in total

1.  Hematopoietic SCT in Iranian children 1991-2012.

Authors:  A A Hamidieh; M Behfar; A E S Babaki; A Jalali; A-S Hosseini; M Jahani; K Alimoghaddam; A Ghavamzadeh
Journal:  Bone Marrow Transplant       Date:  2015-01-19       Impact factor: 5.483

2.  Umbilical cord blood-derived mesenchymal stem cells transplantation decreases incidence of liver cancer in end-stage liver disease patients: a retrospective analysis over 5 years.

Authors:  Le Luo; Chunyou Lai; Tianhang Feng; Yutong Yao; Hua Xue; Guangming Xiang; Lanyun Luo; Xiaolun Huang
Journal:  Am J Transl Res       Date:  2022-08-15       Impact factor: 3.940

3.  Esophagectomy for the patients with squamous cell carcinoma of the esophagus after allogeneic hematopoietic stem cell transplantation.

Authors:  Fumihiko Kato; Hiroyuki Daiko; Jun Kanamori; Yoshihiro Inamoto; Takahiro Fukuda; Koji Hayashi; Yuji Tachimori; Kazuo Koyanagi
Journal:  Int J Clin Oncol       Date:  2019-09-23       Impact factor: 3.402

4.  Identifying Barriers to Umbilical Cord Blood Banking in Jordan: A Cross-Sectional Survey of Obstetricians.

Authors:  Fayez Abdulrazeq; Monica M Matsumoto; Reem Abduljabbar; Amira Al-Hajj; Melad Alayash; Rahaf Ballourah; Sumayya Issak; Zubeida Issak
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2020-10-01

5.  Outcome of match related allogeneic stem cell transplantation procedures performed from 2004 till 2011.

Authors:  Natasha Ali; Salman Naseem Adil; Mohammad Usman Shaikh; Munira Moosajee; Nehal Masood
Journal:  Exp Hematol Oncol       Date:  2012-05-18

6.  In situ buccal carcinoma in a teenager after hematopoietic stem cell transplantation: A case report.

Authors:  Yanbin Liu; Wei Yuan; Man Li; Long Cheng; Jinsuo Yang; Boya Yin; Xin Huang
Journal:  Medicine (Baltimore)       Date:  2020-10-23       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.